Table 3.

Conditional logistic regression–derived ORs and 95% CIs for the association between T2DM and prostate cancer, stratified by selected diabetes-related variables

Control subjects (N = 221,495)Prostate cancer cases (N = 44,352)ORa (95% CI)
Diabetes
 No diabetes212,25542,871Ref
 Diabetes9,2401,4810.80 (0.76–0.85)
Duration
 No diabetes212,25542,871Ref
 1–4 y2,5134340.87 (0.79–0.96)
 5–9 y2,5374280.85 (0.77–0.93)
 10–19 y2,7844340.78 (0.71–0.86)
 20+ y1,4061850.65 (0.56–0.75)
Treatment
 No diabetes212,25542,871Ref
 Diet only2,0553650.89 (0.80–0.99)
 Oral hypoglycemic agents3,7135880.80 (0.74–0.87)
 Insulin1,9482850.72 (0.64–0.81)
 OHA and insulin1,4642340.80 (0.70–0.91)
BMI
 No diabetes212,25542,871Ref
 Diabetes, BMI <251,8363240.87 (0.78–0.97)
 Diabetes, BMI 25—303,9756680.83 (0.77–0.90)
 Diabetes, BMI 30+2,4903500.72 (0.65–0.80)
Microalbuminuria
 No diabetes212,25542,871Ref
 No microalbuminuria4,7026840.73 (0.68–0.79)
 Microalbuminuria2,4284560.92 (0.84–1.02)
Age, years at diabetes diagnosis
 No diabetes212,25542,871Ref
 <501,2241530.63 (0.54–0.74)
 50—592,5463880.77 (0.69–0.85)
 60—693,1855210.82 (0.75–0.89)
 70—791,9183410.88 (0.79–0.98)
 80+367781.04 (0.83–1.30)
Creatinine, μmol/L
 No diabetes212,25542,871Ref
 18—761,5562540.83 (0.73–0.94)
 76–861,6342680.83 (0.74–0.94)
 86–961,6372620.80 (0.71–0.91)
 96–1121,7922760.77 (0.68–0.87)
 112–8911,6582670.78 (0.69–0.88)
HbA1c (quintile)
 No diabetes212,25542,871Ref
 3.5–5.21,8663300.88 (0.79–0.99)
 5.2–5.81,5842680.84 (0.75–0.95)
 5.8,6.41,9863130.79 (0.71–0.88)
 6.4–7.11,6682630.79 (0.70–0.89)
 7.1,14.91,9362770.72 (0.64–0.81)

NOTE: Numbers do not add to total because of missing data.

  • aAdjusted for SES, marital status, comorbidity, age at prostate cancer diagnosis and diabetes prevalence in county of residence.